Q1 2026 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) reported a significant increase in revenue, up 300% year-on-year, driven by deferred revenue recognition related to a new QVET agreement.
- The company has made substantial progress in automating its NuQ Vet Cancer Test, enhancing turnaround times and throughput, which is crucial for scaling the vet business.
- VolitionRX Ltd (VNRX) has expanded its collaborator network, including a non-exclusive agreement with Medical and Biological Labs Co. in Japan, to accelerate disease research and drug development.
- The company achieved a major technical milestone with the successful detection of nucleosomes in capillary blood, expanding the market potential for sepsis testing.
- VolitionRX Ltd (VNRX) is actively engaged in discussions with over a dozen leading diagnostic and liquid biopsy companies to license and commercialize its broad IP and product portfolio.
- Operating expenses increased to $6.3 million from $5.8 million in the same period last year, partly due to severance costs and higher R&D expenses.
- Net cash used in operating activities increased to $5.3 million, reflecting the timing of supplier payments.
- The company did not provide revenue guidance for 2026, citing the unpredictability of revenues at this stage of commercialization.
- VolitionRX Ltd (VNRX) has not yet received the $5 million milestone payment related to its feline cancer test, as it awaits publication of the clinical manuscript.
- The commercialization and licensing discussions, while progressing, are still in various stages of negotiation, indicating potential delays in finalizing agreements.
Hello, everyone. Thank you for standing by. Welcome to Volition Rx Limited's first quarter 2026 earnings conference call.
(Operator Instructions)
This conference is being recorded today, May 15, 2026. I'd now like to turn the conference call over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.
Thank you, and welcome, everyone, to today's earnings conference call for Volition Rx Limited.
Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the Safe Harbour provisions of the Private Securities Litigation Reform Act of 1,995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events.
These statements involve risks, uncertainties and assumptions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
